Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans
Jul 31
MTSR Share Price Performance
US$32.19
5.69 (21.47%)
Price US$32.19
Share PriceUS$32.19
MTSR Community Narratives
There are no narratives available yet.
Metsera, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.93
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Metsera, Inc. Competitors
Snowflake Analysis
About MTSR
- Founded
- 2022
- Employees
- 107
- CEO
- WebsiteView website
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Market Insight
This week, we’re going to look at the U.S. regulatory changes, how adoption has been trending, and one of the risks with the ETFs. If you want some exposure to Bitcoin, at the end, we’ll show you some different ways you can position your portfolio accordingly.
Continue reading
U.S. Market Performance
- 7 Days: -1.5%
- 3 Months: 9.5%
- 1 Year: 14.4%
- Year to Date: 8.4%
Over the last 7 days, the market has dropped 1.5%, driven by a pullback of 3.5% in the Information Technology sector. As for the longer term, the market has actually risen by 14% in the last year. Earnings are forecast to grow by 15% annually. Market details ›